The Cholangiocarcinoma Foundation (CCF) is encouraging healthcare professionals to support the adoption of the new International Classification of Diseases, 11th Revision (ICD-11), and its role in creating more robust epidemiological data for cholangiocarcinoma (CCA).
The new codes go into effect on January 1, 2022, and will allow investigators to identify stratifications in CCA that have been obscured because of the previous coding issues. The new codes are:
2C12.10—Intrahepatic cholangiocarcinoma (carcinoma arising from the intrahepatic bile duct epithelium in any site of the intrahepatic biliary tree).
2C15.0—Extrahepatic cholangiocarcinoma: adenocarcinoma of the biliary tract, distal bile duct (an adenocarcinoma arising from the common bile duct distal to the insertion of the cystic duct).
2C18.0—Hilar cholangiocarcinoma (includes left, right, and common hepatic ducts to the origin of the cystic duct).
These codes additionally provide an opportunity to facilitate more accurate and meaningful epidemiological data for doctors to provide sufficient diagnosis details in medical notes.
CCF is participating in a campaign to bring awareness to the new ICD-11 codes. This campaign includes webinars, infographics, and a specific presentation to explain why better coding is needed to be delivered at the CCF Annual Conference in February 2022. To register for the conference, visit https://cholangiocarcinoma.org/2022-annual-conference.
To sign up for our newsletter or print publications, please enter your contact information below.
